Local Institution

Ann Arbor, Michigan 48109

0 studies enrolling now · 13 studies all time

What they study most

Acute Coronary Syndromes, Atrial Fibrillation, Bladder Cancer, Bladder Neoplasms, Essential Thrombocythemia, Heart Diseases, Heart Failure, Hepatocellular Carcinoma, Kidney Neoplasms, Leukemia, Leukemia, Lymphocytic, Acute, L2, Leukemia, Myeloid, Chronic

Studies at this site

• Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) — Completed
• A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma — Running, not enrolling
• Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation — Completed
• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart — Completed
• Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure — Completed
• A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc) — Withdrawn before enrolling
• Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy — Completed
• Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris — Completed
• Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris — Completed
• Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium — Completed
• A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate — Completed
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy — Stopped early
• A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators — Completed